CVRM disease news and stories
Transforming cardiovascular care and the burden of heart failure
ArticleThe current state of hyperkalaemia in cardiorenal patients
Article
Cardiovascular, Renal and Metabolism (CVRM)
Improving and saving lives for the millions of patients living with CVRM diseases.
Home / Our therapy areas / Cardiovascular, Renal and Metabolism (CVRM)
Our commitment to advancing CVRM treatment
The impacts of CVRM diseases on people, society and our planet are immense and growing, yet they remain underdiagnosed, undertreated and their interconnections under-recognised.1-7 These conditions affect hundreds of millions of people around the world; we estimate that one in three people with a CVRM disease are living with two or more of these chronic diseases.8
澳门葡京赌博游戏的目标是加强护理，改善数百万患有复杂慢性粒细胞增多症的患者的预后, to intervene early to protect vital organs, slow or stop disease progression, and one day even cure these often debilitating, progressive and life-threatening conditions.1
Through understanding the interconnections of these conditions, 澳门葡京赌博游戏能够扩大现有药物的使用范围，并建立世界上最广泛的药物之一, deepest and strongest CVRM pipelines.9 By 2032, we aim to be leading the world in CVRM therapies, helping to change the course and reach of medical practice.
Unmet needs and prevalence in CVRM diseases
100s of millions
of people globally live with CVRM diseases1
One in three
CVRM patients live with two or more of these conditions8
98%
of patients with type 2 diabetes have at least one other CVRM disease10
40%–50%
of patients with heart failure have chronic kidney disease11
Our R&D approach
科学研究正在推进澳门葡京赌博游戏对crvrm疾病如何相互关联的理解. 澳门葡京赌博游戏正在投资下一代治疗药物组合，这些治疗药物可以解决多种风险因素，并解决心肾和心脏代谢疾病的潜在驱动因素，以改善健康结果.
By combining pioneering science, digital technologies, big data and AI with the skills and experience of talented people, our pipeline goes beyond traditional small molecules, monoclonal antibodies and peptides, 包括核苷酸形式，如反义寡核苷酸和小干扰RNA, and novel gene and cell therapies that have the potential to regenerate vital organs.
At the same time, we’re working with world-leading academics, non-governmental organisations (NGOs), biotech and other industry partners, healthcare professionals, patients and policymakers to improve detection and diagnosis, streamline clinical trials, widen access, and get our medicines to more people faster.
Collaboration in CVRM care
We are proud to be working with healthcare professionals, patients, governments and policy makers to improve access to healthcare, and remove barriers to diagnosis and optimal treatment. Our goal is to fundamentally change how CVRM diseases are detected, 诊断和治疗加速医疗实践的变化，为患者带来不同.
ACT on CKD
ACT (Accelerate Change Together) on chronic kidney disease (CKD)是澳门葡京网赌游戏(AstraZeneca)的一个项目，旨在通过合作伙伴关系改变肾脏健康，旨在到2025年将进展为肾衰竭的患者比例降低20%.
ACT on HF
Benevolent AI
作为澳门葡京赌博游戏从大量数据中获取知识以更好地理解疾病生物学方法的一部分, we have collaborated with BenevolentAI. In this collaboration, we are combining our disease area expertise and large, 利用BenevolentAI领先的人工智能和机器学习能力，建立各种数据集，为HF构建知识图谱, CKD, idiopathic pulmonary fibrosis (IPF), and systemic lupus erythematosus.
Healthy Heart Africa
澳门葡京赌博游戏的“健康心脏非洲”方案致力于解决非洲的高血压和日益加重的心血管疾病负担. Since launching in Kenya in 2014, we have conducted over 11 million blood pressure screenings, identified over two million elevated readings, trained over 5,800 healthcare workers, and activated over 700 healthcare facilities. 支持联合国减少非传染性疾病导致过早死亡风险的目标, 澳门葡京赌博游戏希望到2025年，整个非洲有1000万高血压患者.
Make the Change for Kidney Health
Make the Change for Kidney Health brings together patient organisations, 医学专家和业界呼吁各国政府和决策者认识到慢性肾脏疾病(CKD)是一个紧迫的全球卫生优先事项，并实施以患者为中心和基于证据的政策，以便及早发现, diagnosis and immediate access to care and recommended treatments. By doing this we aim to bring the best possible outcomes for patients, healthcare systems, caregivers, the economy and the planet. 该活动由澳门葡京网赌游戏与全球肾脏健康患者联盟共同创建，并由澳门葡京网赌游戏资助和制作.
Our people
Built on an impressive legacy in CVRM, 澳门葡京赌博游戏具有独特的优势，可以为患有crvrm疾病的人建立一个更健康、更长久的未来. Our team of over 1,000 people spans more than 23 functions including early and late R&D, medical and commercial.
Our employees are accomplished and experienced scientists, researchers, clinicians, 以及医疗保健和商业专业人士，他们致力于推进新科学和推动实践变革，使crvrm疾病患者受益.
The CVRM team is led by:
Join our team
Join and help us address CVRM diseases. Our teams are based across the globe, with core hubs in Cambridge, Gaithersburg, Wilmington and Gothenburg. We’re proud to foster a culture of constant exploration, questioning and challenging to find ways to do things differently, and to make a positive difference in patients' lives.
Our medicines
澳门葡京赌博游戏无法在本网站上提供澳门葡京赌博游戏处方药的详细信息, in compliance with regulations. 澳门葡京赌博游戏的药物在个别国家获得了特定用途的批准，澳门葡京赌博游戏为患者提供的信息受当地法规的约束. In some cases, 医疗保健专业人员和患者可以访问当地的澳门葡京网赌游戏网站，以了解有关澳门葡京赌博游戏药物的更多信息. Please note that in some countries we are not allowed to provide very much, or sometimes any, 澳门葡京网赌游戏处方药的信息，所以你应该寻找其他值得信赖的来源. Always ask a healthcare professional for advice about medicines.
Our pipeline for CVRM
Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, 并且可能包括现在在一个或多个主要市场推出的资产(在所有适用的主要市场推出时删除).
References
1. Vos T, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22
2. Sarnak MJ, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(14):1823-38.
3. Tourki B, et al. 保留射血分数的心力衰竭综合征是肥胖患者非消解性炎症的代谢簇. Front Cardiovasc Med. 2021;8:695952.
4. Rangaswami J, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019;139(16):e840-e78.
5. Vogel B, et al. 《澳门葡京网赌游戏》妇女与心血管疾病委员会:到2030年减少全球负担. Lancet. 2021;397(10292):2385-438.
6. Carpio E , et al. 多种族成人慢性肾病患者高血压和心血管危险因素管理:一项全科实践的横断面研究. J Nephrol. 2022;35(3):901-10
7. Virani SS, et al. 心脏病和中风统计-2020年更新:美国心脏协会的一份报告. Circulation. 2020;141(9):e139-e596.
8. AstraZeneca Data on File. REF-200649
9. AstraZeneca [Internet]. Our pipeline. [cited 2023 May 25]. Available from: http://weeshy.ospifse.net/our-therapy-areas/pipeline.html
10. Iglay K, Hannachi H, Joseph Howie P, et al. 2型糖尿病患者合并症的患病率和共患病率. Curr Med Res Opin. Jul 2016;32(7):1243-52. doi:10.1185/03007995.2016.1168291
11. Vijay K, et al. 糖尿病和慢性肾病患者的心力衰竭:挑战和机遇. Cardiorenal Med. (2022) 12 (1): 1–10.
Veeva ID: Z4-62672
Date of preparation: March 2024